Mainline Biosciences, Inc.
🇺🇸United States
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Early Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Early Phase 1
1 (100.0%)A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer
Early Phase 1
Withdrawn
- Conditions
- Ovary CancerAdvanced Solid TumorBreast CancerNon Small Cell Lung CancerPancreatic Neoplasms
- Interventions
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Mainline Biosciences, Inc.
- Registration Number
- NCT05465590
News
No news found